Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
International Cancer Conference Journal
Published in: International Cancer Conference Journal 2/2024

16-03-2024 | Targeted Therapy | Editorial

From gene panel testing to new molecularly targeted therapy

Author: Noriomi Matsumura

Published in: International Cancer Conference Journal | Issue 2/2024

Login to get access

Excerpt

This issue includes a report of a case of MET-amplified neuroendocrine cancer detected by gene panel testing that responded to capmatinib [1]. Capmatinib is approved by the Food and Drug Administration for non-small cell lung cancer with MET exon 14 skipping. However, capmatinib is not approved for MET amplification. Capmatinib was given to this patient under the Patient Application for Multiple Molecularly Targeted Therapies Based on Gene Profiling by Gene Panel Testing programme (jRCTs031190104) [2]. This case report is a good example of the discovery of a novel molecularly targeted therapy based on gene panel testing. …
Literature
1.
2.
Metadata
Title
From gene panel testing to new molecularly targeted therapy
Author
Noriomi Matsumura
Publication date
16-03-2024
Publisher
Springer Nature Singapore
Published in
International Cancer Conference Journal / Issue 2/2024
Electronic ISSN: 2192-3183
DOI
https://doi.org/10.1007/s13691-024-00672-8

Other articles of this Issue 2/2024

International Cancer Conference Journal 2/2024 Go to the issue

Case Report - Genetics

A case of hereditary breast and ovarian cancer syndrome of initially presented as cancer of unknown primary with lymph node metastases unveiled by genetic analysis

Case report - Pathology

Intratumoral metastasis of sigmoid colon cancer to chromophobe renal cell carcinoma: a case report

Case Report - Pathology

Primary signet-ring cell carcinoma of the bladder treated with laparoscopic radical cystectomy: a case report

Case report - Complication

A case of postoperative pancreatitis in patients with renal cell carcinoma with an inferior vena cava tumor thrombus treated by presurgical lenvatinib plus pembrolizumab

Case Report - Complication

Durvalumab plus carboplatin-etoposide treatment in a patient with small-cell lung cancer on hemodialysis: a case report and literature review

Video article

Intracorporeal end-to-end esophagojejunostomy using a circular stapler
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits